It is made available under a CC-BY-NC-ND 4.0 International license .

1	Clinical management, epidemiology, and recurrence of human cystic
2	echinococcosis in a secondary care level hospital in an endemic area of the
3	Andes in Sicuani, Cusco, Peru
4	Roberto Pineda-Reyes <sup>1</sup> , Miguel M. Cabada <sup>2,3</sup> , Bolor Bold <sup>4,5</sup> , Maria L. Morales <sup>2</sup> , Jan
5	Hattendorf <sup>1</sup> , Paola Vergaray <sup>6</sup> , Ruben Bascope <sup>7</sup> , Jakob Zinsstag <sup>1*</sup>
6	<sup>1</sup> One Health Group, Human and Animal Health Unit, Department of Epidemiology and
7	Public Health, Swiss Tropical and Public Health Institute, associated to University of Basel,
8	Allschwil, Switzerland
9	<sup>2</sup> Cusco Branch – Alexander von Humboldt Tropical Medicine Institute, Universidad Peruana
10	Cayetano Heredia, Cusco, Peru
11	<sup>3</sup> Division of Infectious Diseases, Department of Internal Medicine, University of Texas
12	Medical Branch, Galveston, TX, USA
13	<sup>4</sup> School of Global Health, Chinese Centre for Tropical Diseases Research, Shanghai Jiao
14	Tong University School of Medicine, Shanghai 200025, China
15	<sup>5</sup> National Center for Zoonotic Disease, Ulaanbaatar 18131, Mongolia.
16	<sup>6</sup> Departamento de Cirugia, Hospital Alfredo Callo Rodriguez, Sicuani, Cusco, Peru
17	<sup>7</sup> Programa de Control de Enfermedades Zoonoticas, Gerencia Regional de Salud de Cusco,
18	Cusco, Peru
19	* Corresponding author (JZ): E-mail: jakob.zinsstag@swisstph.ch Phone: +41 61 284 81 39
20	Keywords: recurrence, hydatid disease, echinococcosis, Andes, South America
21	Word count: Abstract, 252 words; manuscript text, 3632.
22	Running head: Recurrence of cystic echinococcosis in Sicuani, Cusco, Peru
23	Tables and figures: 5 tables, 1 figure.

It is made available under a CC-BY-NC-ND 4.0 International license .

### 24 Abstract

25	Peru has the highest incidence of human cystic echinococcosis (CE) in South America and
26	most cases are reported in the Central and Southern Peruvian Andes, including the Cusco
27	region. We reviewed medical records of patients with CE admitted between 2010-2019 to a
28	level 2 Hospital in Sicuani, to collect data on the surgical management and disease
29	recurrence in the Canchis province of Cusco. Records of 115 patients were analyzed in
30	detail. The median age was 25 years (IQR, 16-46) and 60% were female. Most patients
31	(68.7%) presented with a single liver cyst. The Gharbi classification was used in 75/107
32	(70.1%) patients with an ultrasound and 91/142 cysts (64.8%). Thirty one (34.1%) were
33	classified as Gharbi I, 33 (36.3%) Gharbi II, 21 (23.1%) Gharbi III, and 6 (6.6%) Gharbi IV.
34	Pre-surgical complications were reported in 41.7%. One hundred two patients underwent
35	surgery. In 46.1%, one cyst spillage prevention measure was documented, 5.9% had two,
36	and one had the three recommended measures. Post-surgical cyst recurrence was reported
37	in 16.5% at a median 32.3 months (IQR, 3.9-46.6) and readmissions in 12.7%. In the
38	multivariable analysis, having ≥3 cysts (OR 9.5, 95% CI 1.3-85.5), having two pre-surgical
39	complications (OR 12.6, 95% CI 1.8-125.6), and receiving pre-surgical albendazole (OR 5.2,
40	95% CI 1.3-23.9) were associated with cyst recurrence. Advanced and complicated CE
41	disease and post-surgical recurrence were common in Sicuani. Standardization of
42	ultrasound staging-guided clinical management along with surgical spillage prevention
43	measures could effectively decrease the disease burden linked to clinical care, improving
44	outcomes and decreasing costs.

It is made available under a CC-BY-NC-ND 4.0 International license .

## 50 Introduction

51	Cystic echinococcosis (CE) is a parasitic zoonosis caused by the metacestode stage of the
52	dog tapeworm Echinococcus granulosus (1). E. granulosus has a global distribution, being
53	endemic in South America, North and East Africa, Central Asia and China (2). Peru has the
54	highest incidence of CE in South America, accounting for 84.8% of all reported cases in year
55	2018 (3). The district of Sicuani in the Cusco region is a highly endemic area in the Southern
56	Peruvian Andes. Up to 45% of CE cases referred to tertiary care hospitals in Cusco are from
57	Sicuani (4). A population survey in four communities also found the highest prevalence in
58	Sicuani (5). The economic and urban expansion of the Sicuani city have created areas
59	where informal livestock slaughter activities, stray dogs, and humans interact closely.
60	Prompt diagnosis and appropriate treatment of cases in Sicuani are crucial to address the
61	burden of CE in the healthcare system.
62	The WHO-Informal Working Group on Echinococcosis (WHO-IWGE) ultrasound staging
63	system is used to diagnose and guide the clinical management of liver CE (6). However,
64	many low- and middle-income countries (LMIC) have not implemented the proposed WHO
65	ultrasound staging exposing patients to unnecessary procedures (7). CE is associated with
66	high post-surgical recurrence risk, with rates that range between 4.7% and 16.4% (8-11).
67	Clinical characteristics such as the cyst size, number of cysts, and presence of
68	complications have been associated with disease severity and recurrence (10, 12, 13).
69	Treatment precautions to avoid cyst rupture and spillage may decrease the risk of
70	recurrence related to surgical care.
71	The expert consensus on diagnosis and treatment of CE recommends the use of hypertonic
72	saline-soaked drapes for surgical field protection, injection of a scolicidal agent into the cyst,
73	and prescription of pre-surgical albendazole (ABZ) to prevent intraabdominal protoscolex
74	spillage during surgery (6). Increasing evidence shows that appropriate standardization of

surgical procedures may be associated with lower risk of recurrence (14-16). Similarly, the

It is made available under a CC-BY-NC-ND 4.0 International license .

- <sup>76</sup> "watch-and-wait" approach for inactive cysts should be the standard of care to spare
- asymptomatic patients from unnecessary treatment (17, 18).
- 78 We conducted a review of medical records of patients hospitalized in the Alfredo Callo
- 79 Rodriguez Hospital in Sicuani during a 10-year period to describe the CE management in
- 80 Sicuani, determine the post-surgical recurrence rate, and the risk factors for recurrence.

- ...

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 98 Methods

### 99 Study design and setting

- 100 This is a review of medical records from patients hospitalized at the Alfredo Callo Rodriguez
- 101 Hospital in Sicuani. This hospital is a level 2 public health center that provides specialty
- 102 medical care to patients from the Canchis and Canas provinces of Cusco (19). We collected
- data from all patients admitted to the hospital for CE between January 1, 2010 and
- 104 December 31, 2019. The pre-COVID-19 period was selected to avoid collecting information
- that could reflects gaps in care or practice of CE treatment in Sicuani because of the public
- 106 health emergency. This timeframe also coincides with the renovation and expansion of
- 107 surgical services in the hospital in 2010.
- 108 The city of Sicuani is the capital of the Canchis province in the Cusco region at an elevation
- 109 of 3,548 meters above sea level. The Sicuani district has an urban population of 47,386 and
- a rural population of 10,441 habitants (20). Sicuani is a commerce center for farmers of the
- surrounding areas and is the second largest city in the Cusco region.

## 112 Study procedures

- 113 Medical record numbers of patients with CE were identified using ICD-10 codes (B67.0-
- 114 B67.9) assigned as the discharge diagnosis through the Hospital's Statistics Department.
- 115 Surgical logbooks were handsearched to ensure all surgical CE cases were retrieved.
- 116 Demographic and clinical data were collected via ODK software (© 2022 Get ODK Inc.,
- 117 California, USA) using an electronic Case Report Form, which was piloted at the start of data
- 118 collection to ensure data accuracy.

119 Definitions

- 120 The three evaluated spillage-prevention measures included the use of drapes soaked on
- 121 hypertonic saline for surgical field protection, injection of hypertonic saline into the cyst prior
- to evacuation of contents, and the prescription of pre-surgical ABZ (6). Post-surgical

It is made available under a CC-BY-NC-ND 4.0 International license .

123 recurrence was defined as the development of a new cyst at or near the site of the

124 previously removed metacestode and/or within a cavity (e.g., peritoneum, pleura) where

- 125 cyst(s) were operated on. The time-to-recurrence was estimated as the time from the
- 126 surgery date until the date of recurrence diagnosis. In one case the date of recurrence was

127 recorded as "2024" and it was assigned the first day of this year as the date. New cyst was

defined as a newly diagnosed cyst in a location different from other operated cysts.

129 *Readmission* was defined as return to inpatient care related to CE after discharge.

- 130 *Readmission rate* was calculated by dividing the number patients with at least one
- readmission by the total number of hospitalization discharges.

132 Cumulative incidence calculation

133 The annual cumulative incidence of new hospital admissions was calculated dividing the

number of new CE hospitalizations per year by the total population at risk each year. The

population at risk was defined as the total population of the Canas and Canchis provinces

136 per year. Population data for years 2015 to 2019 was extracted from a repository database

137 of the Peruvian Ministry of Health and data for years 2009 to 2014 was extracted from CPI

138 database (21, 22).

139 Statistical analysis

140 Data analysis and visualization were performed using the R software, version 4.3.2 (R

141 Foundation for Statistical Computing, Vienna, Austria). Means with standard deviation (SD),

142 medians with interquartile range (IQR), and frequencies were used to assess the

143 distributions of demographic, epidemiological, and clinical characteristics of patients. The

144 association between variables and the outcome 'post-surgical recurrence' was assessed

145 using non-parametric tests such as Chi-Square and Fisher's exact test. A multivariable

- 146 logistic regression analysis was performed to determine independent associations with the
- 147 outcome variable. We assessed a pre-defined model with variables of clinical or
- epidemiological relevance in unadjusted logistic regression analyses for each variable.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 149 These variables included age, sex, duration of symptoms, cyst diameter, number of cysts,
- 150 pre-surgical complications, affected liver lobe or segment, spillage prevention measures,
- 151 post-surgical ABZ, and post-surgical complications. Variables with significant associations in
- the unadjusted models were considered in the multivariable analysis. The multivariable
- 153 model was adjusted for age and sex. A P value of <0.05 was considered statistically
- 154 significant. Confidence intervals were calculated at the 95% level.
- 155 Ethical Statement
- 156 This study was reviewed and approved by the Ethics Committee of Northern and Central
- 157 Switzerland (Ethikkommission Nordwest- und Zentralschweiz, EKNZ) and the Institutional
- 158 Ethics Committee (Comite Institucional de Etica en Investigacion) of the Universidad
- 159 Peruana Cayetano Heredia in Lima, Peru.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 161 **Results**

### 162 Demographic and clinical characteristics

163 One hundred and twenty-five medical record numbers were identified. Six were duplicated, 2 164 were mislabeled as CE, and 2 had missing charts. In total, 115 unique medical records from 165 patients with CE and clinical information were included in the study (**Table 1**). The median 166 age was 25 years (IQR, 16-46) and 60% were female. Most patients (103, 89.6%) were 167 residents of the Canchis province and 73.9% lived in the Sicuani district. Fifty-six patients 168 (48.7%) were referred from primary healthcare centers, and 57.1% of these were referred 169 from the Pampaphalla health center. 170 One hundred eighty-five echinococcal cysts were diagnosed in the 115 patients, 169 were 171 diagnosed upon presentation to the hospital and 16 during readmissions. These involved the 172 liver, lungs, stomach, spleen, duodenum, gallbladder, diaphragm, adnexa, bladder, and 173 colon. Most (142, 84%) were located in the liver, 16 within the abdominal cavity, and 11 in 174 the lungs. Four patients had disseminated liver and intraabdominal cysts. The maximum 175 number of lung cysts per patient was 2. The median largest diameter for liver cyst was 12.8 176 cm (IQR, 9.2-15.0) and for lung cysts was 8.5 cm (IQR, 4.5-12.6). Seventy-seven (67%)

177 patients carried a liver cyst of  $\geq$ 10 cm diameter.

178 Most patients (98, 85.2%) presented with only liver cysts, 7 (6.1%) with both liver and 179 intraabdominal cysts, 5 (4.3%) with liver and lung cysts, and 5 (4.3%) with only lung cysts 180 (**Table 2**). Most patients presented with a single liver cyst (79, 68.7%). Forty-eight (41.7%) 181 cases presented with complicated cysts before surgery, 31 (27%) had one pre-surgical 182 complication, 8 (7%) had two, and 9 (7.8%) had three or more. The most common cyst 183 complications before surgery were infection of the cyst content (17, 14.9%), cysto-biliary 184 fistulas (9, 7.8%), liver abscess (9, 7.8%), cyst rupture (8, 7.0%), and peritonitis (5, 4.3%) 185 (Table 3).

186 Ultrasound diagnosis

medRxiv preprint doi: https://doi.org/10.1101/2024.09.12.24313559; this version posted September 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

187 One hundred seven patients (93%) had a diagnostic ultrasound. In 75 (70.1%), a liver 188 ultrasound was performed and used for staging according to the Gharbi classification (6) and 189 in 20 (18.7%) a liver ultrasound was performed but no staging was reported. Twelve patients 190 had lung cysts, disseminated disease, complicated cysts, or unclear or missing ultrasound 191 reports precluding the use of a cyst diagnostic and management classification. In total, 91 192 (64.8%) of the 142 liver cysts were staged using the Gharbi classification. Thirty-one (34.1%) 193 were Gharbi I, 33 (36.3%) Gharbi II, 21 (23.1%) Gharbi III, and 6 (6.6%) Gharbi IV. Seven 194 (6.1%) patients were diagnosed with inactive cysts, including one who had a Gharbi IV cyst 195 diagnosed intraoperatively. In one of these patients, the cyst was described in the surgical 196 report as containing multiple daughter cysts (Gharbi III). 197 Treatment, protoscolex-spillage prevention measures, and post-surgical complications 198 Only patients with liver and intraabdominal cysts underwent surgery in Sicuani (102, 88.7%). 199 Ninety five of the 102 patients (93.1%) underwent conventional surgery, 6 (5.9%) 200 laparoscopic surgery, and one laparoscopic surgery converted to conventional laparotomy. 201 The most common surgical techniques were cystectomy plus drainage (74, 72.5%) and 202 pericystectomy plus drainage (9, 8.8%) (Table 4). In one case a Gharbi IV cyst was found 203 and not excised and two patients with inactive cysts (2%) underwent excision. In one case 204 the liver cyst was not found during the surgery. None of the patients had a percutaneous 205 procedure performed. In 18 (17.6%) patients, the operative report did not describe the 206 anatomical location of the liver cyst. Seventy (68.6%) patients had right liver lobe cysts, 26 207 (25.5%) left liver lobe cysts, and 12 (11.8%) had cysts in both liver lobes. In 46 (45.1%) 208 patients the liver segment VIII was involved, in 32 (31.4%) the segment VII, in 24 (23.5%) 209 the VI, in 17 (16.7%) the IV, in 12 (11.8%) the V, in 10 (9.8%) the II, in 8 (7.8%) the III, and in 210 one patient the segment I. 211 Forty-seven (46.1%) patients had at least one surgical spillage prevention measure

documented, 6 (5.9%) had two, and only one had the three recommended spillage

213 prevention measures. Pre-surgical ABZ was used in 33 (32.4%) cases, injection of

It is made available under a CC-BY-NC-ND 4.0 International license .

214 hypertonic saline into the cyst before evacuation of contents was used in 16 (15.7%) cases. 215 and drapes soaked with hypertonic saline were used for surgical field protection in 6 (5.9%) 216 cases. Peri-surgical ABZ within 6 hours of surgery was not used in any of the cases (16). 217 ABZ was the only antiparasitic prescribed. In 57 (55.9%) patients, ABZ was prescribed after 218 surgery, in 27 (26.5%) before and after surgery, in 7 (6.9%) no ABZ was prescribed, in 6 219 (5.9%) ABZ was prescribed only before surgery, and in 5 cases the timing of the prescription 220 was unknown. The median post-surgical duration of ABZ treatment prescribed was 30 days 221 (IQR, 22-34) and the median pre-surgical duration of ABZ treatment prescribed was 2 days 222 (IQR, 1-4).

Post-surgical complications occurred in 22 (21.6%) patients. The most common were the development of residual fluid collections (14, 13.7%), post-surgical abscess (3, 2.9%), and biliary leakage (3, 2.9%) (**Table 3**). The three patients with post-surgical liver abscess were readmitted to the hospital.

227 Post-surgical recurrence, readmission, and cumulative incidence

228 One patient required a second surgical intervention within the same hospitalization for post-229 surgical biliary leak, and one required intensive care due to post-surgical hemodynamic 230 instability. Eleven (9.6%) patients were referred to a higher level of care, 9 for treatment of 231 pulmonary CE, 1 for post-surgical shock, and 1 for potential need of post-surgical intensive 232 care. Of these, 10 patients went to the Hospital Regional del Cusco and 1 patient to the 233 Hospital Antonio Lorena in Cusco. Post-surgical recurrence was documented in 16/97 234 (16.5%) patients. The median time to recurrence after surgery was estimated at 32.3 months 235 (IQR, 3.9-46.6). The multivariable logistic regression analysis showed that having  $\geq$ 3 cysts 236 compared to 1 cyst (50% vs 15.1%, OR=9.54, 95% CI 1.33-85.47), having two pre-surgical 237 complications compared to having none (57.1% vs 16.9%, OR=12.62, 95% CI 1.8-125.64), 238 and receiving a prescription for pre-surgical ABZ compared to not receiving it (27.3% vs

It is made available under a CC-BY-NC-ND 4.0 International license .

239 10.9%, OR=5.16, 95% CI 1.33-23.93) were associated with post-surgical recurrence (Figure
240 1).

241	Fourteen (14/110, 12.7%) patients were readmitted to the Hospital de Sicuani at least once,
242	6 did for cyst recurrence, 2 for treatment complications, 2 for complications of a previous
243	cyst plus cyst recurrence, 3 for elective two-stage treatment, and one for a new cyst. One
244	patient had 2 readmissions. Twelve out of the 14 patients with readmissions had active
245	echinococcal cysts. The median age was 40 years (IQR, 26.5-62), 7 (58.3%) were female,
246	and 5 (41.7%) were referred from the Pampaphalla health center. Single liver cyst was the
247	presentation in 9/12 (75%) of patients with readmissions. Readmissions contributed with 16
248	additional cysts to the overall count for the 10-year study period. The annual cumulative
249	incidence of new hospital admissions for CE at the Alfredo Callo Rodriguez Hospital of
250	Sicuani are reported in Table 5.
251	
252	
253	
254	
255	
256	
257	
258	

260

259

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 262 Discussion

263 Our study describes the clinical characteristics and management of CE at a secondary care 264 level hospital located in an endemic area in the Southern Peruvian Andes. We found that 265 most CE patients requiring hospital admission in Sicuani were part of the economically 266 active population and one-third were younger than 18 years. Advanced echinococcal 267 disease was common, with nearly 70% of patients having liver cysts ≥10 cm in diameter and 268 42% presenting with pre-surgical complications. Despite the use of ultrasound in the 269 evaluation of CE in 90% of the cases, the WHO-IWGE system for diagnosis and 270 management of liver CE was not used in any of the patients. Instead, the Gharbi 271 classification was used on a limited number of cysts. Spillage prevention measures were 272 documented in less than half of the surgical procedures performed. One in six patients had 273 recurrence of CE after surgery and one in eight patients was readmitted to the hospital at 274 least once. Our data suggest that educational interventions could improve the medical and 275 surgical management of CE in Hospital Sicuani and decrease the morbidity associated with 276 disease recurrence and surgical procedures.

277 The Alfredo Callo Rodriguez Hospital of Sicuani serves as a referral center to the Canas and 278 Canchis provinces. These provinces have a large young age populations being prominently 279 affected by CE. The latent period of CE, between infection and clinical presentation, typically 280 lasts many years suggesting that active transmission occurs in Sicuani and that it occurs 281 early in life. A large case series of hospitalized patients in the Extremadura and Castilla-282 Leon regions of Spain showed a distribution skewed towards the older age groups with only 283 2% cases presenting in patients younger than 19 years (23, 24). The authors attributed this 284 age distribution in part to the successful interruption of CE transmission by control programs. 285 A similar scenario was described in Chile, where most reported cases between 2018-2022 286 were diagnosed among patients 45 to 74 years (25). Efforts to control CE transmission in the 287 Canas and Canchis provinces were limited to the treatment of dogs in rural areas and

It is made available under a CC-BY-NC-ND 4.0 International license .

sporadic screening of children. A concerted effort with a One Health approach is needed to

289 formulate control strategies in the area.

290 Most of the patients in our study had liver cysts and 41.7% presented with complications. 291 This proportion of complications is comparable with a study in Salamanca, Spain (40.3%) 292 but higher than other case series (4%) (26, 27). Collado-Aliaga and colleagues (26) found in 293 a tertiary care hospital a bigger proportion of mechanical complications (25% vs 20%), 294 including biliary fistulas (13.4% vs 7.8%) and mass effect (5.5% vs 4.4%). We observed a 295 larger proportion of infectious complications (25.2% vs 17.8%), cyst rupture (8.7% vs 2.9%), 296 and cysts >10 cm in diameter (68.7% vs 45% >7 cm). These differences could be due to 297 selection bias from hospital level of care or complexity of the clinical care (secondary vs 298 tertiary care), and differences in healthcare access. 299 Having two pre-surgical complications was associated with increased odds of post-surgical 300 recurrence compared to not having complications. Single complications including cyst 301 rupture and fistulas did not have an association with recurrence. Other studies were also 302 unable to demonstrate associations of infectious, mechanical or allergic complications and 303 recurrence (9, 26). In one of these studies, 64% patients were asymptomatic at the moment 304 of diagnosis, which could indicate that the risk of recurrence depends on more than one 305 clinical variable but on surgical technique performance and post-surgical care (9). Larger 306 cyst diameter has been proposed as a marker of disease severity and a risk factor for 307 recurrence (12). We did not find an association between cyst diameter and pre-surgical 308 complications, recurrence, or readmission. Although other studies reported cysts with 309 smaller sizes (median 6.6 cm and 10 cm vs 13 cm in our cohort), these could not 310 demonstrate an associations with complications or recurrence either (11, 13, 26). We did 311 observe an independent association between increasing number of cysts and the risk of 312 post-surgical recurrence in our patients. Number of cysts has been previously identified as a 313 risk factor for complications and recurrence. For example, Pacifico and colleagues detected 314 four-times increased risk for recurrence among those with  $\geq 3$  cysts, and another study also

It is made available under a CC-BY-NC-ND 4.0 International license .

found having  $\geq$ 3 cysts was an independent risk factor for recurrence (10, 13). This could be the result of large parasitic burden secondary to repeated cycles of infection or subclinical cyst rupture and seeding long prior to hospital admission.

318 Documentation of adequate ultrasound staging was observed in 91 out 142 diagnosed liver 319 cysts. Ultrasound diagnosis is not yet fully implemented in LMIC (7). In none of the cases 320 reviewed in this study the WHO-IWGE staging system was used. The WHO-IWGE 321 classification serves as a guide for the clinical management to either medical, percutaneous, 322 surgical or 'watch and wait' approach (6). Thirty-six (35.3%) patients who underwent surgery 323 in our study presented without complications and had Gharbi I or II liver cysts, being in 5 324 cases between 5-10 cm in diameter and in 30 cases ≥10 cm. Some of these patients could 325 have been candidates for percutaneous treatment (28); however, this treatment option is still 326 not widely available in Peru. Patients with Gharbi III cysts in our study had a greater 327 proportion of post-surgical recurrence (29.4%) compared to the other stages (10.7% of 328 Gharbi I, 7.7% of Gharbi II, and 0% of Gharbi IV). Surgery is the treatment of choice for 329 Gharbi III cysts due to the high recurrence rates reported in percutaneous treatment studies 330 (28, 29). Proposed explanations for these findings include multiple daughter cysts within a 331 solid matrix being more difficult to access and drain, as well as the presence of undetected 332 very small daughter cysts that could not have enough exposure to the scolicidal agent or 333 were not properly drained (29, 30). Moreover, two patients in our study had inactive cysts excised and one patient was referred to Cusco Regional Hospital for management of a 334 335 Gharbi IV cyst. Ultrasound screening for early diagnosis along with standardization of WHO-336 IWGE staging and implementation of percutaneous invasive procedures may improve CE 337 outcomes in Sicuani, decreasing costs, unnecessary procedures and hospitalization time. 338 We found a higher post-surgical recurrence rate in comparison with other studies evaluating 339 this measure (8, 10, 11, 31). This is particularly concerning, when only a minority of patients 340 had documentation of the recommended surgical spillage prevention measures. In some 341 cases, it was described that surgical field drapes were soaked on normal saline or iodine

It is made available under a CC-BY-NC-ND 4.0 International license .

342 rather than hypertonic saline and the instillation of a scolicidal agent into the cyst cavity was 343 performed after the cyst opening and evacuation of contents. Although we did not find a 344 protective association between these measures and recurrence, proper standardization has 345 been associated with null recurrence at 24 months in prospective studies (16). Furthermore, 346 pre-surgical ABZ had a paradoxically positive association with recurrence in our cohort. This 347 phenomenon was observed in other study in which patients receiving antiparasitics were 348 associated with higher risk of recurrence (9). This could be the result of an indication bias in 349 a retrospective study, in which the more complicated patients were treated more carefully 350 and documentation was more precise. Pre-surgical ABZ remains a core measure of 351 protoscolex spillage-prevention in liver CE (28). Prospective studies carefully assessing the 352 appropriate timing and dosing of antiparasitics will help elucidate this clinical gap to improve 353 outcomes.

354 Our study had limitations that should be acknowledged. First, this is a retrospective review of 355 paper-form medical charts with a small sample size. Missing information in certain variables 356 such as ultrasound staging did not allow testing their association with our outcome. Second, 357 as the Hospital Archives Department had a digitalized database of medical record numbers since 2017, cases of years 2010-2016 had to be handsearched in the surgical logbooks. 358 359 Therefore, patients who were hospitalized during this period and did not have surgery are 360 missing in our cohort. Third, the description of symptoms, complications, and management 361 of patients in our study represent the judgement of practicing clinicians in Sicuani during a 362 large time span. These may not concur with the standard of care in other contexts and 363 generalizations should be carefully assessed. Finally, the lack of follow up in some patients 364 may have underestimated our recurrence outcome.

In conclusion, advanced and complicated liver CE and post-surgical recurrence were
 common among hospitalized patients in Sicuani, Cusco, Peru. Practical measures including
 standardization of ultrasound staging-guided clinical management, protoscolex spillage-

It is made available under a CC-BY-NC-ND 4.0 International license .

- 368 prevention measures, and follow-up could effectively decrease the burden linked to clinical
- 369 care, improving outcomes and decreasing costs in Sicuani.

It is made available under a CC-BY-NC-ND 4.0 International license .

### 389 Acknowledgements

- 390 We thank the Alfredo Callo Rodriguez Hospital's Administration Office as well as the
- 391 personnel of the Statistics and Archives Department for their assistance during the study
- 392 period.
- 393

## 394 Financial support

- This study was supported by the "Bologna Master Thesis" funding from the Department of Education of the University of Basel, Switzerland.
- 397

# 398 Conflicts of interest

- 399 The authors have no competing interests.
- 400

### 401 Authors' details

- 402 **RP-R:** Swiss Tropical and Public Health Institute, associated to University of Basel,
- 403 Allschwil, Switzerland, Kreuzstrasse 2, 4123 Allschwil, Switzerland, repineda1@gmail.com;
- 404 MMC: Cusco Branch Alexander von Humboldt Tropical Medicine Institute, Universidad
- 405 Peruana Cayetano Heredia and Infectious Disease Division, University of Texas Medical
- 406 Branch, Galveston Texas, 301 University Boulevard, Rte. 0435, Galveston, TX 77555-0435,
- 407 USA, micabada@utmb.edu; BB: School of Global Health, Chinese Centre for Tropical
- 408 Diseases Research, Shanghai Jiao Tong University School of Medicine, Shanghai 200025,
- 409 China and National Center for Zoonotic Disease, Ulaanbaatar 18131, Mongolia,
- 410 <u>bolor.bold.ch@gmail.com;</u> MLM: Cusco Branch Alexander von Humboldt Tropical
- 411 Medicine Institute, Universidad Peruana Cayetano Heredia, Jr. Jose Carlos Mariategui J6
- 412 Urb. Santa Monica, Distrito Wanchaq 08002, Cusco, Peru, maria.morales.f@upch.pe; JH:
- 413 Swiss Tropical and Public Health Institute, associated to University of Basel, Allschwil,
- 414 Switzerland, Kreuzstrasse 2, 4123 Allschwil, Switzerland, jan.hattendorf@swisstph.ch; PV:
- 415 Departamento de Cirugia, Hospital Alfredo Callo Rodriguez Sicuani, Av. Manuel Callo
- 416 Zevallos Nro. 519, Sicuani, Cusco, Peru, <u>miqxonc21@gmail.com</u>; **RB:** Programa de Control
- 417 de Enfermedades Zoonoticas, Gerencia Regional de Salud de Cusco, Prolongacion de la
- 418 Cultura 1525, Cusco 08003, Peru, <u>bascopecusco@gmail.com</u>; JZ: Swiss Tropical and
- 419 Public Health Institute, associated to University of Basel, Allschwil, Switzerland,
- 420 Kreuzstrasse 2, 4123 Allschwil, Switzerland, jakob.zinsstag@swisstph.ch.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 421 References

- 422 1. Craig PS, McManus DP, Lightowlers MW, Chabalgoity JA, Garcia HH, Gavidia CM,
- 423 et al. Prevention and control of cystic echinococcosis. Lancet Infect Dis. 2007;7(6):385-94.
- 424 2. Deplazes P, Rinaldi L, Alvarez Rojas CA, Torgerson PR, Harandi MF, Romig T, et al.
- 425 Global Distribution of Alveolar and Cystic Echinococcosis. Adv Parasitol. 2017;95:315-493.
- 426 3. PAHO/WHO. Equinococosis: informe epidemiológico en la región de América del Sur
- 427 2018, n.4, 2020: Veterinary Public Health PANAFTOSA PAHO/WHO; 2020 [Available
- 428 from: <u>https://iris.paho.org/handle/10665.2/51942</u>.
- 429 4. Flores Quispe O. Equinococosis quística en niños y adolescentes en los hospitalales
- 430 Regional del Cusco y Adolfo Guevara Velasco, Cusco a 3400 msnm, 2010-2014. Cusco,
- 431 Peru.: San Antonio Abad del Cusco.; 2015.
- 432 5. Tamarozzi F, Hou A, Morales ML, Giordani MT, Vilca F, Mozo K, et al. Prevalence
- and Risk Factors for Human Cystic Echinococcosis in the Cusco Region of the Peruvian
- 434 Highlands Diagnosed Using Focused Abdominal Ultrasound. Am J Trop Med Hyg.
- 435 2017;96(6):1472-7.

Brunetti E, Kern P, Vuitton DA, Writing Panel for the W-I. Expert consensus for the
diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop.

- 438 2010;114(1):1-16.
- 439 7. Bold B, Hattendorf J, Shagj A, Tserendovdon B, Ayushkhuu T, Luvsandorj A, et al.
- 440 Patients with cystic echinococcosis in the three national referral centers of Mongolia: A
- 441 model for CE management assessment. PLoS Negl Trop Dis. 2018;12(8):e0006686.
- 442 8. Kapan M, Kapan S, Goksoy E, Perek S, Kol E. Postoperative recurrence in hepatic
  443 hydatid disease. J Gastrointest Surg. 2006;10(5):734-9.
- 444 9. Velasco-Tirado V, Romero-Alegría Á, Belhassen-García M, Alonso-Sardón M,
- 445 Esteban-Velasco C, López-Bernús A, et al. Recurrence of cystic echinococcosis in an
- 446 endemic area: a retrospective study. BMC Infect Dis. 2017;17(1):455.

It is made available under a CC-BY-NC-ND 4.0 International license .

447	10.	El Malki HO, El Mejdoubi Y, Souadka A, Zakri B, Mohsine R, Ifrine L, et al. Does
-----	-----	--

- primary surgical management of liver hydatid cyst influence recurrence? J Gastrointest Surg.
  2010;14(7):1121-7.
- 450 11. Yosra K, Ghada H, Bochra A, Fatma T, Said J, Riadh J. Predictive Factors of Liver

451 Hydatid Cyst Recurrence in Children. J Pediatr Surg. 2023;58(12):2362-7.

- 452 12. Bedioui H, Ayari H, Bouslama K, Maghrebi H, Hsairi H, Jouini M, et al. [Recurrence of
- 453 hydatid cyst of liver: predictive factors: Tunisian experience]. Bull Soc Pathol Exot.

454 2012;105(4):265-9.

455 13. Pacifico J, Cabrera R, Salgado-Diaz S, Mormontoy W, Suarez-Ognio L. Factors

456 associated with pre-surgical complications in patients with cystic echinococcosis from

457 endemic areas of Peru. Rev Peru Med Exp Salud Publica. 2021;38(1):33-40.

458 14. Al-Saeedi M, Ramouz A, Khajeh E, El Rafidi A, Ghamarnejad O, Shafiei S, et al.

459 Endocystectomy as a conservative surgical treatment for hepatic cystic echinococcosis: A

systematic review with single-arm meta-analysis. PLoS Negl Trop Dis.

461 2021;15(5):e0009365.

462 15. Abbasi Dezfouli S, El Rafidi A, Aminizadeh E, Ramouz A, Al-Saeedi M, Khajeh E, et

463 al. Risk factors and management of biliary leakage after Endocystectomy for hepatic cystic

echinococcosis. PLoS Negl Trop Dis. 2023;17(10):e0011724.

465 16. Al-Saeedi M, Khajeh E, Hoffmann K, Ghamarnejad O, Stojkovic M, Weber TF, et al.

466 Standardized endocystectomy technique for surgical treatment of uncomplicated hepatic

467 cystic echinococcosis. PLoS Negl Trop Dis. 2019;13(6):e0007516.

468 17. Lissandrin R, Tamarozzi F, Mariconti M, Manciulli T, Brunetti E, Vola A. Watch and

469 Wait Approach for Inactive Echinococcal Cyst of the Liver: An Update. Am J Trop Med Hyg.

470 2018;99(2):375-9.

471 18. Junghanss T, da Silva AM, Horton J, Chiodini PL, Brunetti E. Clinical management of

472 cystic echinococcosis: state of the art, problems, and perspectives. Am J Trop Med Hyg.

473 2008;79(3):301-11.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 474 19. Gerencia Regional de Salud Cusco. Analisis de Situacion de Salud Canchis Cusco,
- 475 Peru: Red Nacional de Epidemiologia RENACE Peru; 2020 [Available from:
- 476 https://www.redsaludcce.gob.pe/Modernidad/archivos/epidemiologia/ASIS/ASIS Canchis 2
- 477 <u>020.pdf</u>.
- 478 20. Instituto Nacional de Estadistica e Informatica (INEI). Censo 2018, Resultados
- 479 Definitivos, Region Cusco. Lima, Peru: Gobierno del Peru; 2018.
- 480 21. Ministerio de Salud del Peru. Estadistica Poblacional Lima: Ministerio de Salud del
- 481 Peru.; 2023 [Available from: <u>https://www.minsa.gob.pe/reunis/data/poblacion\_estimada.asp</u>.
- 482 22. Compania Peruana de Estudios de Mercado y Opinion Publica (CPI Peru).
- 483 Estadisticas Poblacionales Peru: CPI Peru; [Available from:
- 484 https://cpi.pe/banco/estadisticas-poblacionales.html.
- 485 23. Lopez-Bernus A, Belhassen-Garcia M, Prieto-Vicente AJ, Alonso-Sardon M, Carpio-
- 486 Perez A, Velasco-Tirado V, et al. [Epidemiological update of hydatid disease in hospitals in
- 487 the public health system of Extremadura (2003-2012)]. Enferm Infecc Microbiol Clin.
- 488 2016;34(4):232-6.
- 489 24. Lopez-Bernus A, Belhassen-Garcia M, Alonso-Sardon M, Carpio-Perez A, Velasco-
- 490 Tirado V, Romero-Alegria A, et al. Surveillance of Human Echinococcosis in Castilla-Leon
- 491 (Spain) between 2000-2012. PLoS Negl Trop Dis. 2015;9(10):e0004154.
- 492 25. Ministerio de Salud Gobierno de Chile. Informe: Situación de la Equinococosis
- 493 Quística/Hidatidosis en Chile, 2018-2022. Chile: Ministerio de Salud Gobierno de Chile;
- 494 2023 [Available from: https://diprece.minsal.cl/wp-content/uploads/2024/03/INFORME-
- 495 <u>HIDATIDOSIS-2018-2022.pdf</u>.
- 496 26. Collado-Aliaga J, Romero-Alegria A, Alonso-Sardon M, Muro A, Lopez-Bernus A,
- 497 Velasco-Tirado V, et al. Complications Associated with Initial Clinical Presentation of Cystic
- 498 Echinococcosis: A 20-year Cohort Analysis. Am J Trop Med Hyg. 2019;101(3):628-35.
- 499 27. Salgado Díaz S, Suarez-Ognio L, Cabrera R. Características clínicas y
- 500 epidemiológicas de la equinococosis quística registradas en un área endémica en los Andes
- 501 centrales del Perú. Neotropical Helminthology. 2007;1(2):69-83.

It is made available under a CC-BY-NC-ND 4.0 International license .

502	28.	Kuehn R, Uchiumi LJ, Tamarozzi F. Treatment of uncomplicated hepatic cystic
503	echin	ococcosis (hydatid disease). Cochrane Database Syst Rev. 2024;7(7):CD015573.
504	29.	Kabaalioglu A, Ceken K, Alimoglu E, Apaydin A. Percutaneous imaging-guided
505	treatn	nent of hydatid liver cysts: do long-term results make it a first choice? Eur J Radiol.
506	2006;	59(1):65-73.
507	30.	Men S, Hekimoglu B, Yucesoy C, Arda IS, Baran I. Percutaneous treatment of
508	hepat	ic hydatid cysts: an alternative to surgery. AJR Am J Roentgenol. 1999;172(1):83-9.
509	31.	Velasco-Tirado V, Romero-Alegria A, Belhassen-Garcia M, Alonso-Sardon M,
510	Esteb	an-Velasco C, Lopez-Bernus A, et al. Recurrence of cystic echinococcosis in an
511	ender	mic area: a retrospective study. BMC Infect Dis. 2017;17(1):455.
512		
513		
212		
514		
515		
516		
F 4 7		
517		
518		
519		
520		
521		
522		
523		
F 2 4		
524		

It is made available under a CC-BY-NC-ND 4.0 International license .

525 **Table 1.** General characteristics of 115 patients hospitalized for cystic echinococcosis during the

526 period 2010 to 2019 at the Alfredo Callo Rodriguez Hospital of Sicuani, Cusco, Peru.

527

Variable <sup>*</sup> – no. (%)	All patients	Pre-surgical complications <sup>a</sup>		
. ,	(n=115)	No (n=63)	Yes (n=48)	
Age group	/			
<18 years	34 (29.6)	18 (28.6)	15 (31.3)	
18-64 years	67 (58.3)	41 (65.1)	25 (52.1)	
≥65 years	14 (12.2)	4 (6.3)	8 (16.7)	
Female	69 (60.0)	35 (55.6)	31 (64.6)	
District of residence				
Sicuani	85 (73.9)	47 (74.6)	38 (79.2)	
Marangani	7 (6.1)	6 (9.5)	1 (2.1)	
Other	18 (15.7)	10 (15.9)	8 (16.7)	
Referred from primary care	EC (10 7)	20 (60 2)	10 (27 E)	
center	56 (48.7)	38 (60.3)	18 (37.5)	
Location of cyst				
Only liver	98 (85.2)	57 (90.5)	38 (79.2)	
Liver and other intraabdominal	7 (6.1)	4 (6.3)	2 (4.2)	
Only lung	5 (4.4)	1 (1.6)	4 (8.3)	
Liver and lung	5 (4.4)	1 (1.6)	4 (8.3)	
Number of cysts		()	(0.0)	
Single cyst	84 (73.0)	49 (77.8)	33 (68.8)	
2 cysts	20 (17.4)	9 (14.3)	9 (18.8)	
≥3 cysts	11 (9.6)	5 (7.9)	6 (12.5)	
Largest cyst diameter	(0.0)	0 (1.0)	0 (12.0)	
<5 cm	3 (2.6)	1 (1.6)	2 (4.2)	
5-10 cm	28 (24.3)	16 (25.4)	12 (25)	
≥10 cm	79 (68.7)	45 (71.4)	31 (64.6)	
Anemia severity	10 (00.1)	40 (11.4)	01 (04.0)	
No anemia	57 (49.6)	33 (52.4)	24 (50.0)	
Mild	27 (23.5)	19 (30.2)	8 (16.7)	
Moderate	22 (19.1)	10 (15.9)	12 (25.0)	
Severe	3 (2.6)	0 (0.0)	3 (6.3)	
Ultrasound performed	107 (93.0)	62 (98.4)	45 (93.8)	
Ultrasound staging	107 (93.0)	02 (90.4)	45 (95.6)	
Gharbi staging	75 (65.2)	48 (76.2)	27 (56 2)	
	· · ·	· · ·	27 (56.3)	
No staging method	20 (17.4)	8 (12.7)	12 (25.0)	
Other Treatment approach	12 (10.4)	6 (9.5)	6 (12.5)	
Treatment approach		07 (50 7)	00(44.7)	
Surgery + post-ABZ	57 (49.6)	37 (58.7)	20 (41.7)	
Surgery + pre- & post-ABZ	27 (23.5)	15 (23.8)	12 (25.0)	
No treatment	10 (8.7)	2 (3.2)	8 (16.7)	
Only surgery	7 (6.1)	4 (6.3)	3 (6.3)	
Surgery + pre-ABZ	6 (5.2)	3 (4.8)	3 (6.3)	
Only ABZ	3 (2.6)	2 (3.2)	1 (2.1)	
Post-surgical complications	22 (19.1)	12 (19.0)	10 (20.8)	
Referred to higher care center	11 (9.6)	2 (3.2)	9 (18.8)	
Post-surgical recurrence	16 (16.5) <sup>b</sup>	8 (12.7)	6 (12.5)	
Readmission	$\frac{14(12.7)^{c}}{(12.7)^{c}}$	9 (14.3)	5 (10.4)	

<sup>\*</sup>Non-available data in variables "sex" (n=1), "district of residence" (n=5), "largest cyst diameter" (n=5), duration of symptoms (n=12), length of stay (n=5), anemia severity (n=6).

<sup>a</sup>Non-available data in 4 patients. *ABZ*, albendazole, *pre-*, pre-surgical, *post-*, post-surgical.

<sup>b</sup> 16/97 surgically treated patients with complete charts.

<sup>c</sup> 14/110 discharged patients with complete charts.

It is made available under a CC-BY-NC-ND 4.0 International license .

534	<b>Table 2.</b> Clinical presentation characteristics by anatomical location of cysts.
-----	--

535

Variable <sup>*</sup>	Only liver (n=98)	Liver and other intraabdominal (n=7)	Liver and lung (n=5)	Only lung (n=5)
Median age (IQR)	28 (17-47.5)	21 (13-41)	18 (6-80)	18 (8-23)
Female – no. (%)	57 (58.2)	3 (42.9)	5 (100.0)	4 (80.0)
Symptoms – no. (%)			. ,	. ,
Abdominal pain	94 (95.9)	6 (85.7)	2 (40.0)	0 (0.0)
Nausea	26 (26.5)	2 (28.6)	0 (0.0)	0 (0.0)
Vomiting	22 (22.4)	1 (14.3)	0 (0.0)	0 (0.0)
Abdominal mass	6 (6.1)	0 (0.0)	0 (0.0)	0 (0.0)
Fever	5 (5.1)	0 (0.0)	1 (20.0)	3 (60.0)
Shortness of breath	2 (2.0)	0 (0.0)	3 (60.0)	4 (80.0)
Cough	0 (0.0)	0 (0.0)	4 (80.0)	5 (Ì00.Ó)
Hemoptysis	0 (0.0)	0 (0.0)	1 (20.0)	1 (20.0)
Vomica	0 (0.0)	0 (0.0)	1 (20.0)	1 (20.0)
Median duration of			. ,	. ,
symptoms (IQR)	31 (8-92)	19.5 (14.3-120.8)	13 (7-15)	20 (8-62)
Number of cysts - no. (%)				
Single cyst	79 (80.6)	0 (0.0)	0 (0.0)	5 (100.0)
2 cysts	16 (16.3)	1 (14.3)	3 (60.0)	0 (0.0)
≥3 cysts	3 (3.1)	6 (85.7)	2 (40.0)	0 (0.0)
Median largest cyst	. ,	. ,		
diameter (IQR)	13 (9.6-15.1)	9.5 (7.4-13.1)	10.9 (10.7-12)	5 (4-9.8)
Median unadjusted	4E (40 E 40 0)	4E 4 (4 4 7 4E E)	40 (40 6 40 5)	10 0 (10 10 0)
hemoglobin (g/dl) (IQR)	15 (13.5-16.3)	15.1 (14.7-15.5)	13 (12.6-13.5)	13.6 (12-13.6)
Anemia severity – no. (%)				
No anemia	49 (50.0)	5 (71.4)	1 (20.0)	2 (40.0)
Mild	23 (23.5)	1 (14.3)	2 (40.0)	1 (20.0)
Moderate	19 (19.4)	0 (0.0)	2 (40.0)	1 (20.0)
Severe	2 (2.0)	0 (0.0)	0 (0.0)	1 (20.0)
Median WBC count (×10 <sup>9</sup> /L) (IQR)	9.2 (7.5-12.3)	10.3 (8.5-14.4)	11.5 (7.6- 12.1)	10.2 (8.0- 11.0)
Median eosinophil count (cells/µL) (IQR)	128 (0-300)	352 (176-548)	0 (0-470)	35 (0-81.6)
Median platelet count (×10 <sup>9</sup> /L) (IQR)	315.2 (298.4- 350.7)	389 (340-392)	337 (260-378)	492 (357-550)
Median AST (units/L) (IQR)	10.1 (7-18.8)	9 (8-9.5)	39 (22-40.5)	NA
Median ALT (units/L) (IQR)	12 (9-17.7)	11 (9.5-11)	36 (22.5-46.5)	NA
Median total bilirubin (mg/dL) (IQR)	1.02 (0.84- 1.39)	0.89 (0.86-1.02)	0.24 (0.18- 0.31)	NA
Post-surgical recurrence – no. (%)	13 (13.3)	3 (42.9)	0 (0.0)	0 (0.0)
Readmission – no. (%)	12 (12.2)	2 (28.6)	0 (0.0)	0 (0.0)

<sup>5</sup>Non-available data in variables "sex" (n=1), "duration of symptoms" (n=12), "largest cyst diameter" (n=5), "pre-surgical complications" (n=4), "hemoglobin" (n=6), "anemia severity" (n=6), "WBC count" (n=7), "eosinophil count" (n=28), "platelet count" (n=18), "AST" (n=63), "ALT" (n=63), "total bilirubin" (n=59), "post-surgical recurrence" (n=5), and "readmission"

540 (n=5).

541 ALT, alanine transaminase, AST, aspartate transaminase, IQR, interquartile range, WBC,

542 white blood cell.

It is made available under a CC-BY-NC-ND 4.0 International license .

- **Table 3.** Pre-surgical, intraoperative, and post-surgical complications by anatomical
- 544 location of cysts.

Complication type <sup>*</sup>	n=115 (%)
Pre-surgical (n=48, 41.7%)	
Infectious (n=29, 25.2%)	
Purulent cyst fluid	17 (14.8)
Abscess	9 (7.8)
Peritonitis	5 (4.4)
Pneumonia	5 (4.4)
Cholecystitis	2 (1.7)
Cholangitis	1 (0.9)́
Mechanical (n=23, 20%)	· · · · ·
Fistula	11 (9.6)
Cysto-biliary	9 (7.8)
Cysto-pleural-bronchial	1 (0.9)
Cholecysto-gastric	1 (0.9)
Cyst rupture or vomica	10 (8.7)
Mass effect	5 (4.4)
Respiratory (n=5, 4.4%)	• ()
Respiratory insufficiency	5 (4.4)
Hemorrhagic (n=3, 2.6%)	0 ( 11 1)
Hemoptysis	2 (1.7)
Hemorrhagic cyst fluid	1 (0.9)
Allergic (n=3, 2.6%)	1 (0.0)
Rash/urticaria	3 (2.6)
Other (n=3, 2.6%)	0 (2.0)
Abdominal trauma	1 (0.9)
Ectopic pregnancy	1 (0.9)
Pregnancy	1 (0.9)
Intraoperative (n=2, 1.7%)	1 (0.0)
Anaphylactic shock	1 (0.9)
Cardiac arrest	1 (0.9)
Hemoperitoneum	1 (0.9)
Spleen laceration	1 (0.9)
Post-surgical (n=22, 19.1%)	1 (0.0)
Residual collection	14 (12.2)
Abscess	3 (2.6)
Biliary leakage	3 (2.6)
Cutaneous fistula	2 (1.7)
Adherences	1 (0.9)
	· · ·
Hemorrhage Post-cardiac arrest	1 (0.9)
	1 (0.9) 1 (0.9)
Sepsis Wound infaction	· · ·
*Patients may have more than one	1 (0.9)

It is made available under a CC-BY-NC-ND 4.0 International license .

**Table 4.** Surgical techniques performed among 102 patients during the study period. In one

553 case the liver cyst could not be found and the patient was discharged on albendazole.

Surgical technique	Patients (n=102)
Cystectomy plus drainage	74 (72.5)
Pericystectomy plus drainage	9 (8.8)
Cystectomy	5 (4.9)
Pericystectomy	4 (3.9)
Laparoscopic cystectomy plus drainage	3 (2.9)
Partial cystectomy plus drainage	2 (2.0)
Enucleation and cystectomy	1 (1.0)
Laparoscopic cystectomy	1 (1.0)
Laparoscopic drainage of abscessed cyst	1 (1.0)

**Table 5.** Annual cumulative incidence of new hospital admissions for human cystic echinococcosis at the Alfredo Callo Rodriguez Hospital of

 Sicuani during the period 2010-2019.

Year	New hospital admissions for CE			All hospital admissions, including readmissions			Denvilation	Cumulative
	Patients	atients Echinococcal cysts		Admissions Echinoco		coccal cysts	<ul> <li>Population</li> <li>at risk<sup>§</sup></li> </ul>	incidence
	n=115 (%)	n=169 (%)	Mean cysts per patient (SD)	n=126 (%)	n=185 (%)	Mean cysts per patient (SD)	- at risk*	×100,000
2019	21 (18.3)	33 (19.5)	1.57 (1.12)	22 (17.5)	35 (18.9)	1.59 (1.10)	144,607	14.5
2018	16 (13.9)	21 (12.4)	1.31 (0.79)	17 (13.5)	22 (11.9)	1.29 (0.77)	143,826	11.1
2017	16 (13.9)	27 (16.0)	1.69 (1.78)	19 (15.1)	30 (16.2)	1.58 (1.64)	143,059	11.2
2016	12 (10.4)	17 (10.1)	1.42 (1.17)	15 (11.9)	20 (10.8)	1.33 (1.05)	142,266	8.4
2015	20 (17.4)	31 (18.3)	1.55 (0.83)	23 (18.2)	38 (20.5)	1.65 (1.07)	141,444	14.1
2014	9 (7.8)	11 (6.5)	1.22 (0.44)	9 (7.1)	11 (6.0)	1.22 (0.44)	141,900	6.3
2013	5 (4.4)	9 (5.3)	1.8 (0.84)	5 (4.0)	9 (4.9)	1.8 (0.84)	142,300	3.5
2012	9 (7.8)	11 (6.5)	1.22 (0.44)	9 (7.1)	11 (6.0)	1.22 (0.44)	142,800	6.3
2011	5 (4.4)	7 (4.1)	1.4 (0.89)	5 (4.0)	7 (3.8)	1.4 (0.89)	143,200	3.5
2010	2 (1.7)	2 (1.2)	1.0 (0.00)	2 (1.6)	2 (1.1)	1.0 (0.00)	143,600	1.4

\*Not counting one patient readmitted in 2020 for a liver cyst, one patient readmitted in 2020 for multiple liver and intraabdominal cysts, and two patients readmitted for drainage of post-surgical liver abscesses.

<sup>§</sup>Combining the Canas and Canchis provinces total population.

CE, cystic echinococcosis, SD, standard deviation.

It is made available under a CC-BY-NC-ND 4.0 International license

It is made available under a CC-BY-NC-ND 4.0 International license .

**Figure 1.** Forest plot exhibiting the multivariable logistic regression analysis for postsurgical recurrence. The left column shows the explanatory variables. Odds ratios and confidence intervals in black represent unadjusted logistic regression models for each independent variable. Odds ratios and confidence intervals in blue represent the multivariable analysis.

ABZ, albendazole, Cl, confidence interval, OR, odds ratio.

